These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37161855)

  • 1. Venous thromboembolism risk in cancer patients receiving first-line immune checkpoint inhibitor versus chemotherapy.
    Li A; May SB; La J; Martens KL; Amos CI; Flowers CR; Do NV; Brophy MT; Chitalia V; Ravid K; Gaziano JM; Fillmore NR
    Am J Hematol; 2023 Aug; 98(8):1214-1222. PubMed ID: 37161855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.
    Khorana AA; Palaia J; Rosenblatt L; Pisupati R; Huang N; Nguyen C; Barron J; Gallagher K; Bond TC
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors.
    Icht O; Darzi N; Shimony S; Jacobi O; Reinhorn D; Landman Y; Mutai R; Averbuch I; Shochat T; Spectre G; Raanani P; Rotem O; Dudnik E; Peled N; Zer A; Leader A
    J Thromb Haemost; 2021 May; 19(5):1250-1258. PubMed ID: 33605020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database study.
    Iwai C; Jo T; Konishi T; Fujita A; Michihata N; Matsui H; Fushimi K; Yasunaga H
    Cancer Immunol Immunother; 2023 Nov; 72(11):3581-3591. PubMed ID: 37540262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
    Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venous thromboembolism events in patients with advanced cancer on immune checkpoint inhibitors.
    Kartolo A; Yeung C; Moffat GT; Hanna L; Hopman W; Baetz T
    Immunotherapy; 2022 Jan; 14(1):23-30. PubMed ID: 34758641
    [No Abstract]   [Full Text] [Related]  

  • 7. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.
    Moik F; Chan WE; Wiedemann S; Hoeller C; Tuchmann F; Aretin MB; Fuereder T; Zöchbauer-Müller S; Preusser M; Pabinger I; Ay C
    Blood; 2021 Mar; 137(12):1669-1678. PubMed ID: 33067632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of Cancer-Associated Venous Thromboembolism in Patients With Solid and Hematologic Neoplasms in the Veterans Affairs Health Care System.
    Martens KL; Li A; La J; May SB; Swinnerton KN; Tosi H; Elbers DC; Do NV; Brophy MT; Gaziano JM; Lotfollahzadeh S; Chitalia V; Ravid K; Fillmore NR
    JAMA Netw Open; 2023 Jun; 6(6):e2317945. PubMed ID: 37306999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis.
    Yamaguchi T; Shimizu J; Matsuzawa R; Watanabe N; Horio Y; Fujiwara Y
    BMC Cancer; 2024 Jul; 24(1):842. PubMed ID: 39009968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy.
    Hill H; Robinson M; Lu L; Slaughter D; Amin A; Mileham K; Patel JN
    Thromb Res; 2021 Dec; 208():71-78. PubMed ID: 34742139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and Outcomes of Cancer Patients With Venous Thromboembolic Events After Treatment With Immune Checkpoint Inhibitors.
    Dutra B; Garcia-Rodriguez V; Garcia R; Szafron D; Abraham F; Khurana S; Lockhart J; Amin R; Wang Y; Thomas A
    Am J Clin Oncol; 2023 Mar; 46(3):94-100. PubMed ID: 36735530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
    Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
    JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of first-line immune checkpoint inhibitor and anti-angiogenic agent combination therapy for Kirsten rat sarcoma viral antigen-mutant advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
    Tsukada A; Morita C; Shimizu Y; Uemura Y; Naka G; Takasaki J; Nokihara H; Izumi S; Hojo M
    Thorac Cancer; 2024 Sep; 15(25):1854-1862. PubMed ID: 39086088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis.
    Zhao Y; He Y; Wang W; Cai Q; Ge F; Chen Z; Zheng J; Zhang Y; Deng H; Chen Y; Lao S; Liang H; Liang W; He J
    Lancet Oncol; 2024 Oct; 25(10):1347-1356. PubMed ID: 39159630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study.
    Wei Q; Deng T; Wu J; Zeng H; Qi C; Tan S; Zhang Y; Huang Q; Pu X; Xu W; Li W; Tian P; Li Y
    BMC Cancer; 2024 Mar; 24(1):393. PubMed ID: 38549044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between immune checkpoint inhibitor medication and uveitis: a population-based cohort study utilizing TriNetX database.
    Kuo HT; Chen CY; Hsu AY; Wang YH; Lin CJ; Hsia NY; Tsai YY; Wei JC
    Front Immunol; 2023; 14():1302293. PubMed ID: 38264654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of a nomogram model for predicting venous thromboembolism risk in lung cancer patients treated with immune checkpoint inhibitors: A cohort study in China.
    Liang G; Hu Z; Xu Q; Wang G; Wang Y; Li X; Zhang W; Lei H
    Cancer Med; 2024 Aug; 13(16):e70115. PubMed ID: 39162396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
    Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
    ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.